2 completed, 1 terminated, 1 unknown. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
Follow Neuroendocrine: new trials by email Literature Review of Neuroendocrine trials Research Report on Neuroendocrine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor | Phase 1 / Phase 2 | Unknown | Ochsner Health System | 250 | 2014-03-01 | 2014-01-17 |
| Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers JI-101, Everolimus - Cancer, Neuroendocrine | Phase 1 / Phase 2 | Terminated | University of Utah | 19 | 2010-09-01 | 2014-10-06 |
| Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) MK-2206 - PANCREAS, Neuroendocrine | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 11 | 2010-07-01 | 2016-02-18 |
| RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Everolimus - Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma | Phase 2 | Completed | Novartis Pharmaceuticals | 73 | 2009-06-24 | 2019-01-25 |
Neuroendocrine Tumors (3) · Carcinoid Tumor (2) · Adenoma, Islet Cell (1) · Apudoma (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Colonic Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Adenocarcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenoma (1) · Adnexal Diseases (1) · Carcinoma (1)
Everolimus (2) · 1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea (1) · MK 2206 (1)
Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · Ochsner Health System (1) · University of Utah (1)
United States (3) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Diane Reidy-Lagunes, MD,MS (1) · Sunil Sharma, MD (1)